II. Indications
- Non-Q-Wave Myocardial Infarction
- High risk Unstable Angina
- Angioplasty
III. Contraindications
- Recent major bleeding
IV. Mechanism
- Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
- Inhibits Fibrinogen binding to Platelets
V. Medications
-
Abciximab (ReoPro)
- Percutaneous Coronary Intervention (PCI)
- Load: 0.25 mg/kg IV bolus given 10 to 60 minutes before PCI
- Infuse: 0.125 mcg/kg/min up to 10 mcg/min IV for 12 hours
- Unstable Angina or non-ST-elevation Myocardial Infarction pending PCI within 24 hours
- Dosing as for PCI, with infusion up to 18 to 24 hours, completing at one hour post-PCI
- Coronary Aneursym in Kawasaki Disease
- Off label use for age >2 months old
- Dosing as used in PCI
- Percutaneous Coronary Intervention (PCI)
-
Eptifibatide (Integrilin)
- Acute Coronary Syndrome
- Load: 180 mcg/kg IV bolus
- Infuse: 2 mcg/kg/min IV for up to 72 hours
- Percutaneous Coronary Intervention (PCI)
- Bolus 180 mcg/kg IV immediately before procedure and again 10 minutes after the first dose
- Infuse: 2 mcg/kg/min IV for 18 to 24 hours after procedure (at least 12 hours)
- Renal Impairment (GFR<50 ml/min)
- Decrease infusion rate to 1 mcg/kg/min
- Obesity (weight >121 kg)
- Maximum bolus dose: 22.6 mg
- Maximum infusion rate 15 mg/hour (7.5 mg/hour if GFR<50 ml/min)
- Acute Coronary Syndrome
-
Tirofiban (Aggrastat)
- Non-ST elevation Myocardial Infarction (NSTEMI)
- Load: 25 mcg/kg over 5 min
- Infuse: 0.15 mcg/kg/min for up to 18 hours
- Slow rate to 0.075 mcg/kg/min if GFR <=60 ml/min
- Non-ST elevation Myocardial Infarction (NSTEMI)